Seattle Startup Takes Precision Oncology to the Next Step: Carla Grandori, CEO, SEngine
Academic Industrial Partnership for Translation of Technologies for Cancer Diagnosis and Treatment
Cure First, a non-profit research organization, and SEngine Precision Medicine co-authored one of 27 high-profile papers published today by Cell Press.
SEngine partners with Knight Cancer Institute at OHSU and Fred Hutch researchers to bring personalized, cancer-fighting tech to patients.
SEngine team presenting five posters at American Association for Cancer Research annual conference.
Got f(x)? Join The Society for Functional Precision Medicine (SFPM) and help advance the science and medicine of direct functional testing of patient cancer cells. SFPM's mission is to facilitate implementation of functional assays into clinical care.
CELL Press released 27 papers which are part of the PanCancer Atlas. SEngine in-depth analysis of the MYC oncogene across 11,000 samples and 33 tumor types published in Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas.
It's official. Research by Cure First and SEngine Precision Medicine scientists including CEO and Founder Carla Grandori, MD. Ph.D. and Principal Scientist Franz Schaub identifying a common gene in nearly 30% of all cancers just published in Cell Press.
Incredible speakers tackle key challenges. The Seattle conference tackles the future of functional precision oncology.
An important read about the foundation and future of functional precision medicine to help current cancer patients and the oncologists who treat them. As told by SEngine Precision Medicine CEO Carla Grandori, MD. Ph.D.
Personalized Oncology Screening Results Validated in Method Developed by Seattle Cancer Research Organizations. Click here to read the paper in Cancer Discovery (PMID_28331002).
SEngine Precision Medicine Signs New Licensing Agreement with Fred Hutchinson Cancer Research Center
Nature Medicine cites SEngine collaborative work with Cornell Institute for Precision Medicine. July 2017 23(7) 796-799, (PMID_28697178)
A Road Map for Precision Cancer Medicine Using Personalized Models. Cancer Discovery May 2017 PMID_28461408
SEngine CLIA certification makes the P.A.R.I.S. cancer test available to patients. The P.A.R.I.S. Assay employs live cancer cells to evaluate the response to >120 drugs on a given patient cancer sample in a matter of few weeks.
There are hundreds of drugs that treat cancer, and every patient reacts differently to each of them. That means doctors are often left in the dark when choosing which treatment to give a patient and patients often don’t get the most effective treatment for them.
Former V.P. of technology transfer from Fred Hutch, Ulrich Mueller joins Seattle Cancer-Fighting Startup SEngine Precision Medicine as Chief Business Officer